

Dr. rer. nat. Annett Maderer (<https://orcid.org/0000-0001-9891-5046>)

Publikationen (Stand 01.06.2022)

Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Schimanski CC, Bahre R, Gockel I, **Müller A**, Frerichs K, Hörner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T, Schuler M, Achenbach T, Junginger T, Galle PR, Moehler M. Br J Cancer. 2006 Jul 17;95(2):210-7. Epub 2006 Jul 4. PMID: 16819541 PMCID: PMC2360625 DOI: 10.1038/sj.bjc.6603251

Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy? Drescher D, Moehler M, Gockel I, Frerichs K, **Müller A**, Dünschede F, Borschitz T, Biesterfeld S, Holtmann M, Wehler T, Teufel A, Herzer K, Fischer T, Berger MR, Junginger T, Galle PR, Schimanski CC. World J Gastroenterol. 2007 Jul 14;13(26):3605-9. PMID: 17659711 PMCID: PMC4146800 DOI: 10.3748/wjg.v13.i26.3605

VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. Moehler M, Frings C, **Mueller A**, Gockel I, Schimanski CC, Biesterfeld S, Galle PR, Holtmann MH. World J Gastroenterol. 2008 Jul 14;14(26):4156-67. PMID: 18636661 PMCID: PMC2725377 DOI: 10.3748/wjg.14.4156

Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. Lyros O, **Mueller A**, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M. Int J Cancer. 2010 Sep 1;127(5):1197-208. doi: 10.1002/ijc.25137.

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Moehler M, **Mueller A**, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S; German Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2011 Jun;22(6):1358-66. doi: 10.1093/annonc/mdq591. Epub 2010 Nov 30.

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Moehler M, **Mueller A**, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR; German Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Jul;47(10):1511-20. PMID: 21561763 DOI: 10.1016/j.ejca.2011.04.006

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. **Mueller A**, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M. Cancer Chemother Pharmacol. 2012 Jun;69(6):1601-15. doi: 10.1007/s00280-012-1869-z. Epub 2012 Apr 29.

Novel 3-Azaindolyl-4-arylmaleimides exhibiting potent antiangiogenic efficacy, protein kinase inhibition, and antiproliferative activity. Ganser C1, Laueremann E, **Maderer A**, Stauder T, Krumb JP, Plutizki S, Kindler T, Moehler M, Dannhardt G. J Med Chem. 2012 Nov 26;55(22):9531-40. doi: 10.1021/jm301217c. Epub 2012 Nov 2.

Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy. Wehler TC, Hamdi S, **Maderer A**, Graf C, Gockel I, Schmidtman I, Hainz M, Berger MR, Theobald M, Galle PR, Moehler M, Schimanski CC. Int J Colorectal Dis. 2013 Mar;28(3):385-98. doi: 10.1007/s00384-012-1551-2. Epub 2012 Sep 15.

High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, Bowman ED, **Mueller A**, Schad A, Shimomura M, Hinoi T, Aoyagi K, Sasaki H, Okajima M, Ohdan H, Galle PR, Yasui W, Harris CC. Int J Cancer. 2014 Apr 15;134(8):1926-34. doi: 10.1002/ijc.28522. Epub 2013 Nov 8.

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Thomaidis T, **Maderer A**, Al-Batran SE, Kany J, Pauligk C, Steinmetz K, Schad A, Hofheinz R, Schmalenberg H, Homann N, Galle PR, Moehler M. BMC Cancer. 2014 Jul 1;14:476. doi: 10.1186/1471-2407-14-476.

Moguntinones--new selective inhibitors for the treatment of human colorectal cancer. **Maderer A**, Plutizki S, Kramb JP, Göpfert K, Linnig M, Khillimberger K, Ganser C, Lauermann E, Dannhardt G, Galle PR, Moehler M. Mol Cancer Ther. 2014 Jun;13(6):1399-409. doi: 10.1158/1535-7163.MCT-13-0224. Epub 2014 Apr 17.

Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. Thomaidis T, **Maderer A**, Formentini A, Bauer S, Trautmann M, Schwarz M, Neumann W, Kittner JM, Schad A, Link KH, Rey JW, Weinmann A, Hoffman A, Galle PR, Kornmann M, Moehler M. J Exp Clin Cancer Res. 2014 Oct 2;33:83. doi: 10.1186/s13046-014-0083-8.

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Moehler M, **Maderer A**, Schimanski C, Kanzler S, Denzer U, Kolligs FT, Ebert MP, Distelrath A, Geissler M, Trojan J, Schütz M, Berie L, Sauvigny C, Lammert F, Lohse A, Dollinger MM, Lindig U, Duerr EM, Lubomierski N, Zimmermann S, Wachtlin D, Kaiser AK, Schadmand-Fischer S, Galle PR, Woerns M; Working Group of Internal Oncology. Eur J Cancer. 2014 Dec;50(18):3125-35. doi: 10.1016/j.ejca.2014.09.013. Epub 2014 Oct 15.

Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?! Moehler M, Thomaidis T, Zeifri C, Barhoom T, Marquardt J, Ploch P, Schattenberg J, **Maderer A**, Schimanski CC, Weinmann A, Woerns MA, Kranich AL, Warnecke JM, Galle PR. J Cancer Res Clin Oncol. 2015 Mar;141(3):515-22. doi: 10.1007/s00432-014-1829-6. Epub 2014 Sep 19.

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. Moehler M, Gepfner-Tuma I, **Maderer A**, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, Wilke H, Al-Batran SE, Rafiyan MR, Weißinger F, Schmoll HJ, Kullmann F, von Weikersthal LF, Siveke JT, Weusmann J, Kanzler S, Schimanski CC, Otte M, Schollenberger L, Koenig J, Galle PR. BMC Cancer. 2016 Aug 31;16:699. doi: 10.1186/s12885-016-2736-9.

Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal Cancer. Rades D, **Maderer A**, Panzner A, Hunold P, Sivanathan V, Schmidberger H, Moehler MH. Onco Targets Ther. 2017 May 2;10:2389-2401. PMID: 28476848 DOI: 10.21873/anticancer.11620

Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAOSTO-0801). Michael Stahl[#], **Annett Maderer[#]**, Florian Lordick, Andre L. Mihaljevic, Stefan Kanzler, Thomas Hoehler, Peter Thuss-Patience, Stefan Mönig, Volker Kunzmann, Sebastian Schroll, Andreas Sandermann, Andrea Tannapfel, Hans-Joachim Meyer, Christoph Schuhmacher, Hansjochen Wilke, Markus Moehler on behalf of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Oesophageal and Gastric Cancer Working Group and the Chirurgische Arbeitsgemeinschaft Onkologie (CAOGI/DGAV) of the German Cancer Society. Eur J Cancer. 2018 Mar 1;93:119-126. doi: 10.1016/j.ejca.2018.01.079.^{#contributed equally}

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial. Nagel M, Schulz J, **Maderer A**, Goepfert K, Gehrke N, Thomaidis T, Thuss-Patience PC, Al-Batran SE, Hegewisch-Becker S, Grimminger P, Galle PR, Möhler M, Schattenberg JM. Tumour Biol. 2018 Mar;40(3):1010428318764007. doi: 10.1177/1010428318764007

Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: A randomized placebo-controlled phase II study (EORTC 40071). Markus Moehler, Arno Schad, **Annett Maderer**, Ajlan Atasoy, Murielle E Mauer, Carmela Caballero, Thomas Thomaidis, Jestinah. M. Mahachie John, Istvan Lang, Eric Van Cutsem, João Freire, Manfred P. Lutz, Arnaud Roth, on behalf of the EORTC Gastrointestinal Tract Cancer Group. *Cancer Chemother Pharmacol*. 2018 Aug 13. doi: 10.1007/s00280-018-3667-8. [Epub ahead of print]

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. Markus Moehler; **Annett Maderer**; Anne Ehrlich; Friedrich Foerster; Arno Schad; Tanja Nickolay; Christian Ruckes; Arndt Weinmann; Visvakanth Sivanathan; Jens Marquardt; Peter Robert Galle; Marcus Woerns; Thomas Thomaidis. *BMC Cancer*. 2019 Jan 11;19(1):55. doi: 10.1186/s12885-018-5223-7.

Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. Alexander Desuki, Frank Staib, Ines Gockel, Markus Moehler, Hauke Lang, Stefan Biesterfeld, **Annett Maderer**, Peter R. Galle, Martin R. Berger and Carl C. Schimanski. *Canadian Journal of Gastroenterology and Hepatology*. Volume 2019, Article ID 2920493, 12 pages, <https://doi.org/10.1155/2019/2920493>

Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases. Lang H, Baumgart J, Heinrich S, Tripke V, Passalacqua M, **Maderer A**, Galle PR, Roth W, Kloth M, **Moehler M**. *Ann Surg*. 2019 Nov;270(5):799-805. doi: 10.1097/SLA.0000000000003527.

Young-onset Gastric Cancer and Epstein-Barr Virus (EBV) - A Major Player in the Pathogenesis? Assaf Moore, Elad Hikri, Tal Goshen-Lago, Tamar Barkan, Sara Morgenstern, Elena Brook, **Annett Maderer**, Wilfried Roth, Noa Gordon, Hanoch Kashtan, Baruch Brenner, Markus Moehler, Irit Ben Aharon. *BMC Cancer*, 2020 (1), 34, PMID: 31937281 PMCID: PMC6961297 DOI: 10.1186/s12885-020-6517-0

Cisplatin and 5-fluorouracil With or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients With Non-Resectable, Advanced or Metastatic Oesophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase III AIO/EORTC Trial (POWER). M Moehler[#], **A Maderer[#]**, P C Thuss-Patience, B Brenner, J Meiler, T J Ettrich, R-D Hofheinz, S E Al-Batran, A Vogel, L Mueller, M P Lutz, F Lordick, M Alsina, K Borchert, R Greil, W Eisterer, A Schad, J Slotta-Huspenina, E Van Cutsem, S Lorenzen. *Ann Oncol*. Feb 2020 31 (2), 228-235, PMID: 31959339 DOI: 10.1016/j.annonc.2019.10.018 **#contributed equally**

Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2). D Rades, T Bartscht, P Hunold, H Schmidberger, L König, J Debus, C Belka, N Homann, P Spillner, C Petersen, T Kuhnt, R Fietkau, K Ridwelski, K Karcher-Kilian, A Kranich, S Männikkö, S E Schild, **A Maderer**, M Moehler. *Strahlenther Onkol*, 2020 Sep;196(9):795-804. doi: 10.1007/s00066-020-01646-4. Epub 2020 Jun 12.

The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. M Michel, L Kaps, **A Maderer**, P R Galle, M Moehler. *Cancers (Basel)*, 2021 May 11;13(10):2296. doi: 10.3390/cancers13102296.

CXCR4 and hif-1 α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset. **Annett Maderer**, Frederic Fiteni, Erik Tanis, Murielle Mauer, Thomas Schmitt, Daniela E Aust, Manfred P Lutz, Felicitas Roelofson, Christiane Gog, Arndt Weinmann, Claus H Koehne, Markus Moehler, Thomas Thomaidis. *Acta Oncol*, . 2021 Aug 6;1-5. doi: 10.1080/0284186X.2021.1959057.

Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients. Anna Haupts, Anne Vogel, Sebastian Foersch, Monika Hartmann, **Annett Maderer**, Nicolas Wachter, Tobias Huber, Werner Kneist, Wilfried Roth, Hauke Lang, Markus Moehler & Nils Hartmann. *Sci Rep*. 2021 Aug 18;11(1):16745. doi: 10.1038/s41598-021-95006-6.

Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). Markus Moehler, Gunnar Folprecht, Volker Heinemann, Julian Walter Holch, **Annett Maderer**, Stefan Kasper, Susanna Hegewisch-Becker, Jan Schröder, Friedrich Overkamp, Frank Kullmann, Wolf Otto Bechstein, Matthias Vöhringer, Robert Öllinger, Florian Lordick, Michael Geißler, Armin Schulz-Abelius, Bernhard Linz, Helga Bernhard, Andreas Paul, Irene Schmidtman, Karin Potthoff, Carl Christoph Schimanski. Int J Cancer. 2021 Nov 22. doi: 10.1002/ijc.33881.

A randomized, nonblinded clinical phase III trial evaluating regorafenib plus nivolumab (RegoNivo) versus standard chemotherapy in refractory advanced gastroesophageal junction cancer (GEJC). **Maderer, A.**, Lorenzen, S., Thuss-Patience, P. et al. Regorafenib und Nivolumab (RegoNivo) versus Drittlinie bei Therapie-resistenten Ösophagus-Magen-Karzinomen (GEJC). Forum 37, 163–165 (2022). <https://doi.org/10.1007/s12312-022-01050-2>

Buchartikel

„Sequenztherapie bei gastrointestinalen Tumoren: Kolorektales Karzinom – Magenkarzinom – Pankreaskarzinom“ (UNI-MED Verlag AG, D-28323 Bremen. PDF licensed to SERVIER Deutschland GmbH;) von Prof. Dr. Sylvie Lorenzen und Prof. Dr. Florian Lordick haben Sie den Beitrag „Zukünftige Strategien beim fortgeschrittenen oder metastasierten Magenkarzinom“ verfasst (Kapitel 7, s. Anhang). 2019

Patente

2011

Erteilung des Anwendungspatentes, Use of 3-(indolyl)- or 3-(azaindolyl)-4-aryl male-imide derivatives in cancer management (09179984.1 -2101). Gerd Dannhardt, Jan-Peter Kramb, Stanislav Plutizki, Markus Möhler, **Annett Müller**

2015, Erfindungsmeldung

Angiogenese-/ Kinase-Inhibierung durch Maleinimid-Derivate: Synthese, Metabolismus und pharmakologisches Profil (UMZ-201 5-355). Gerd Dannhardt, Eva Leuermann, Christopher Ganser, Markus Möhler, Rene Mönnikes, **Annett Maderer**